The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity

The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with ob...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Antonella Mosca [verfasserIn] Luca Della Volpe [verfasserIn] Anna Alisi [verfasserIn] Nadia Panera [verfasserIn] Giuseppe Maggiore [verfasserIn] Andrea Vania [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2022

Schlagwörter:	GH nonalcoholic fatty liver disease fibrosis IGF1

Übergeordnetes Werk:	In: Metabolites - MDPI AG, 2012, 12(2022), 12, p 1221
Übergeordnetes Werk:	volume:12 ; year:2022 ; number:12, p 1221

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/metabo12121221

Katalog-ID:	DOAJ083029044

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ083029044
003	DE-627
005	20240414150511.0
007	cr uuu---uuuuu
008	230311s2022 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/metabo12121221 \|2 doi
035			\|a (DE-627)DOAJ083029044
035			\|a (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a QR1-502
100	0		\|a Antonella Mosca \|e verfasserin \|4 aut
245	1	4	\|a The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied.
650		4	\|a GH
650		4	\|a nonalcoholic fatty liver disease
650		4	\|a fibrosis
650		4	\|a IGF1
653		0	\|a Microbiology
700	0		\|a Luca Della Volpe \|e verfasserin \|4 aut
700	0		\|a Anna Alisi \|e verfasserin \|4 aut
700	0		\|a Nadia Panera \|e verfasserin \|4 aut
700	0		\|a Giuseppe Maggiore \|e verfasserin \|4 aut
700	0		\|a Andrea Vania \|e verfasserin \|4 aut
773	0	8	\|i In \|t Metabolites \|d MDPI AG, 2012 \|g 12(2022), 12, p 1221 \|w (DE-627)718627164 \|w (DE-600)2662251-8 \|x 22181989 \|7 nnns
773	1	8	\|g volume:12 \|g year:2022 \|g number:12, p 1221
856	4	0	\|u https://doi.org/10.3390/metabo12121221 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2218-1989/12/12/1221 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2218-1989 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 12 \|j 2022 \|e 12, p 1221

Indexfelder

author_variant	a m am l d v ldv a a aa n p np g m gm a v av
matchkey_str	article:22181989:2022----::hrlotehg1xsnhdvlpetfalipdar
hierarchy_sort_str	2022
callnumber-subject-code	QR
publishDate	2022
allfields	10.3390/metabo12121221 doi (DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf DE-627 ger DE-627 rakwb eng QR1-502 Antonella Mosca verfasserin aut The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology Luca Della Volpe verfasserin aut Anna Alisi verfasserin aut Nadia Panera verfasserin aut Giuseppe Maggiore verfasserin aut Andrea Vania verfasserin aut In Metabolites MDPI AG, 2012 12(2022), 12, p 1221 (DE-627)718627164 (DE-600)2662251-8 22181989 nnns volume:12 year:2022 number:12, p 1221 https://doi.org/10.3390/metabo12121221 kostenfrei https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf kostenfrei https://www.mdpi.com/2218-1989/12/12/1221 kostenfrei https://doaj.org/toc/2218-1989 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 12, p 1221
spelling	10.3390/metabo12121221 doi (DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf DE-627 ger DE-627 rakwb eng QR1-502 Antonella Mosca verfasserin aut The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology Luca Della Volpe verfasserin aut Anna Alisi verfasserin aut Nadia Panera verfasserin aut Giuseppe Maggiore verfasserin aut Andrea Vania verfasserin aut In Metabolites MDPI AG, 2012 12(2022), 12, p 1221 (DE-627)718627164 (DE-600)2662251-8 22181989 nnns volume:12 year:2022 number:12, p 1221 https://doi.org/10.3390/metabo12121221 kostenfrei https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf kostenfrei https://www.mdpi.com/2218-1989/12/12/1221 kostenfrei https://doaj.org/toc/2218-1989 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 12, p 1221
allfields_unstemmed	10.3390/metabo12121221 doi (DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf DE-627 ger DE-627 rakwb eng QR1-502 Antonella Mosca verfasserin aut The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology Luca Della Volpe verfasserin aut Anna Alisi verfasserin aut Nadia Panera verfasserin aut Giuseppe Maggiore verfasserin aut Andrea Vania verfasserin aut In Metabolites MDPI AG, 2012 12(2022), 12, p 1221 (DE-627)718627164 (DE-600)2662251-8 22181989 nnns volume:12 year:2022 number:12, p 1221 https://doi.org/10.3390/metabo12121221 kostenfrei https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf kostenfrei https://www.mdpi.com/2218-1989/12/12/1221 kostenfrei https://doaj.org/toc/2218-1989 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 12, p 1221
allfieldsGer	10.3390/metabo12121221 doi (DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf DE-627 ger DE-627 rakwb eng QR1-502 Antonella Mosca verfasserin aut The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology Luca Della Volpe verfasserin aut Anna Alisi verfasserin aut Nadia Panera verfasserin aut Giuseppe Maggiore verfasserin aut Andrea Vania verfasserin aut In Metabolites MDPI AG, 2012 12(2022), 12, p 1221 (DE-627)718627164 (DE-600)2662251-8 22181989 nnns volume:12 year:2022 number:12, p 1221 https://doi.org/10.3390/metabo12121221 kostenfrei https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf kostenfrei https://www.mdpi.com/2218-1989/12/12/1221 kostenfrei https://doaj.org/toc/2218-1989 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 12, p 1221
allfieldsSound	10.3390/metabo12121221 doi (DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf DE-627 ger DE-627 rakwb eng QR1-502 Antonella Mosca verfasserin aut The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity 2022 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied. GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology Luca Della Volpe verfasserin aut Anna Alisi verfasserin aut Nadia Panera verfasserin aut Giuseppe Maggiore verfasserin aut Andrea Vania verfasserin aut In Metabolites MDPI AG, 2012 12(2022), 12, p 1221 (DE-627)718627164 (DE-600)2662251-8 22181989 nnns volume:12 year:2022 number:12, p 1221 https://doi.org/10.3390/metabo12121221 kostenfrei https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf kostenfrei https://www.mdpi.com/2218-1989/12/12/1221 kostenfrei https://doaj.org/toc/2218-1989 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 12 2022 12, p 1221
language	English
source	In Metabolites 12(2022), 12, p 1221 volume:12 year:2022 number:12, p 1221
sourceStr	In Metabolites 12(2022), 12, p 1221 volume:12 year:2022 number:12, p 1221
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	GH nonalcoholic fatty liver disease fibrosis IGF1 Microbiology
isfreeaccess_bool	true
container_title	Metabolites
authorswithroles_txt_mv	Antonella Mosca @@aut@@ Luca Della Volpe @@aut@@ Anna Alisi @@aut@@ Nadia Panera @@aut@@ Giuseppe Maggiore @@aut@@ Andrea Vania @@aut@@
publishDateDaySort_date	2022-01-01T00:00:00Z
hierarchy_top_id	718627164
id	DOAJ083029044
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ083029044</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414150511.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/metabo12121221</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ083029044</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR1-502</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antonella Mosca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">GH</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nonalcoholic fatty liver disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fibrosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IGF1</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Microbiology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luca Della Volpe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Alisi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nadia Panera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Maggiore</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Vania</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Metabolites</subfield><subfield code="d">MDPI AG, 2012</subfield><subfield code="g">12(2022), 12, p 1221</subfield><subfield code="w">(DE-627)718627164</subfield><subfield code="w">(DE-600)2662251-8</subfield><subfield code="x">22181989</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:12, p 1221</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/metabo12121221</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2218-1989/12/12/1221</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2218-1989</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2022</subfield><subfield code="e">12, p 1221</subfield></datafield></record></collection>
callnumber-first	Q - Science
author	Antonella Mosca
spellingShingle	Antonella Mosca misc QR1-502 misc GH misc nonalcoholic fatty liver disease misc fibrosis misc IGF1 misc Microbiology The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity
authorStr	Antonella Mosca
ppnlink_with_tag_str_mv	@@773@@(DE-627)718627164
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	QR1-502
illustrated	Not Illustrated
issn	22181989
topic_title	QR1-502 The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity GH nonalcoholic fatty liver disease fibrosis IGF1
topic	misc QR1-502 misc GH misc nonalcoholic fatty liver disease misc fibrosis misc IGF1 misc Microbiology
topic_unstemmed	misc QR1-502 misc GH misc nonalcoholic fatty liver disease misc fibrosis misc IGF1 misc Microbiology
topic_browse	misc QR1-502 misc GH misc nonalcoholic fatty liver disease misc fibrosis misc IGF1 misc Microbiology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Metabolites
hierarchy_parent_id	718627164
hierarchy_top_title	Metabolites
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)718627164 (DE-600)2662251-8
title	The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity
ctrlnum	(DE-627)DOAJ083029044 (DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf
title_full	The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity
author_sort	Antonella Mosca
journal	Metabolites
journalStr	Metabolites
callnumber-first-code	Q
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2022
contenttype_str_mv	txt
author_browse	Antonella Mosca Luca Della Volpe Anna Alisi Nadia Panera Giuseppe Maggiore Andrea Vania
container_volume	12
class	QR1-502
format_se	Elektronische Aufsätze
author-letter	Antonella Mosca
doi_str_mv	10.3390/metabo12121221
author2-role	verfasserin
title_sort	role of the gh/igf1 axis on the development of mafld in pediatric patients with obesity
callnumber	QR1-502
title_auth	The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity
abstract	The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied.
abstractGer	The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied.
abstract_unstemmed	The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	12, p 1221
title_short	The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity
url	https://doi.org/10.3390/metabo12121221 https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf https://www.mdpi.com/2218-1989/12/12/1221 https://doaj.org/toc/2218-1989
remote_bool	true
author2	Luca Della Volpe Anna Alisi Nadia Panera Giuseppe Maggiore Andrea Vania
author2Str	Luca Della Volpe Anna Alisi Nadia Panera Giuseppe Maggiore Andrea Vania
ppnlink	718627164
callnumber-subject	QR - Microbiology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/metabo12121221
callnumber-a	QR1-502
up_date	2024-07-03T15:09:16.586Z
_version_	1803571016856764416
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ083029044</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414150511.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2022 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/metabo12121221</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ083029044</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1002b3d44b63440a929838b32ea4acdf</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR1-502</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Antonella Mosca</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The anomalies of the Growth Hormone (GH)/Insulin-like Growth Factor-1 (IGF1) axis are associated with a higher prevalence of Metabolic Associated Fatty Liver Disease (MAFLD) and with a more rapid progression towards fibrosis, cirrhosis, and end-stage liver disease. A total of 191 adolescents with obesity [12–18 years] were consecutively enrolled between January 2014 and December 2020 and underwent liver biopsy to diagnose MAFLD severity. In all patients GH, IGF1 and Insulin-like Growth Factor-Binding Protein 3 (IGFBP3) were measured. Patients with inflammation and ballooning have significantly lower values of GH and IGF1 than those without (GH: 5.4 vs. 7.5 ng/mL; IGF1 245 vs. 284 ng/mL, <i<p</i< < 0.05). GH and IGF1 were also negatively correlated with fibrosis’ degree (r = −0.51, <i<p</i< = 0.001, and r = −0.45, <i<p</i< = 0.001, respectively). Only GH correlated with TNF-a (r = −0.29, <i<p</i< = 0.04) and lobular inflammation (r = −0.36, <i<p</i< = 0.02). At multivariate regression, both GH and IGF1 values, after adjustment for age, sex and BMI, were negatively associated with HOMA-IR but above all with fibrosis (GH→β = −2.3, <i<p</i< = 0.001, IGF1→β = −2.8, <i<p</i< = 0.001). Even in the pediatric population, a reduction of GH input in the liver directly promotes development of de novo hepatic lipogenesis, steatosis, fibrosis and inflammation. The possible role of recombinant GH administration in adolescents with obesity and severe MAFLD deserves to be studied.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">GH</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nonalcoholic fatty liver disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">fibrosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">IGF1</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Microbiology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Luca Della Volpe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Alisi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nadia Panera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Giuseppe Maggiore</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Andrea Vania</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Metabolites</subfield><subfield code="d">MDPI AG, 2012</subfield><subfield code="g">12(2022), 12, p 1221</subfield><subfield code="w">(DE-627)718627164</subfield><subfield code="w">(DE-600)2662251-8</subfield><subfield code="x">22181989</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:12</subfield><subfield code="g">year:2022</subfield><subfield code="g">number:12, p 1221</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/metabo12121221</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1002b3d44b63440a929838b32ea4acdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2218-1989/12/12/1221</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2218-1989</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">12</subfield><subfield code="j">2022</subfield><subfield code="e">12, p 1221</subfield></datafield></record></collection>
score	7.399047

Nicht das Richtige dabei?

Schreiben Sie uns!

The Role of the GH/IGF1 Axis on the Development of MAFLD in Pediatric Patients with Obesity

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?